Marta Rychert
Overview
Explore the profile of Marta Rychert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Withanarachchie V, Rychert M, Wilkins C
Drug Alcohol Rev
. 2025 Feb;
PMID: 39967064
Introduction: Women are emerging as a key demographic for medicinal cannabis (MC) use in countries that have implemented MC reforms. However, research on mothers' experiences of consuming MC remains limited...
2.
Randerson S, Casswell S, Borell B, Rychert M, Gordon L, Lin E, et al.
Drug Alcohol Rev
. 2025 Jan;
44(2):459-470.
PMID: 39838758
Introduction: Many countries, including Aotearoa New Zealand, have socioeconomic and ethnic inequities in alcohol outlet density, yet the potential contribution of alcohol licensing systems is almost unexplored. After licensing reforms...
3.
Wilkins C, Romeo J, Rychert M, Graydon-Guy T
Harm Reduct J
. 2024 Nov;
21(1):192.
PMID: 39501355
Background: The substitution of cannabis for alcohol and other drugs has been conceptualised in a harm reduction framework as where cannabis is used to reduce the negative side-effects, addiction potential,...
4.
Sanchez Lozano C, Wilkins C, Rychert M
J R Soc N Z
. 2024 Oct;
53(2):219-233.
PMID: 39439919
The New Zealand policy response to methamphetamine contamination of housing has resulted in reduction of public housing stock, award of significant remediation costs and evictions. The New Zealand Tenancy Tribunal...
5.
Rychert M, Wilkins C
N Z Med J
. 2024 Oct;
137(1604):73-86.
PMID: 39418607
Aim: To evaluate the implementation of the New Zealand Medicinal Cannabis Scheme (MCS), including how products, prices, prescribing and patient access have evolved since 2020. Method: Analysis of administrative data...
6.
Diesfeld K, Rychert M, Surgenor L, Kelly O, Kersey K
Psychiatr Psychol Law
. 2024 Jun;
31(3):574-586.
PMID: 38895726
A recent decision reveals how a New Zealand's disciplinary tribunal promoted justice for an unwell lawyer in a case of professional misconduct. In 2023, the Lawyers and Conveyancers Disciplinary Tribunal...
7.
DMello K, Chan G, Hall W, Rychert M, Wilkins C, Hammond D
Am J Drug Alcohol Abuse
. 2023 Aug;
49(5):640-651.
PMID: 37624645
Vaping is an increasingly popular mode of cannabis use. Few studies have characterized the role of flavors in cannabis e-liquids. To explore the prevalence of flavored vaping liquids, including differences...
8.
Belackova V, Rychert M, Wilkins C, Pardal M
Clin Ther
. 2023 Jul;
45(6):551-559.
PMID: 37414506
There is ongoing debate about what policy approaches to cannabis use might best address health and social related harm. Profit-driven, adult-use cannabis markets have been introduced in the United States...
9.
Withanarachchie V, Rychert M, Wilkins C
J Prim Health Care
. 2023 Jun;
15(2):135-146.
PMID: 37390030
Introduction The New Zealand Medicinal Cannabis Scheme (NZMCS) was established in April 2020 with the aim of expanding access to quality controlled medicinal cannabis products and developing a domestic medicinal...
10.
Crossin R, Cleland L, Wilkins C, Rychert M, Adamson S, Potiki T, et al.
J Psychopharmacol
. 2023 Jun;
37(9):891-903.
PMID: 37353972
Aims: The harms arising from psychoactive drug use are complex, and harm reduction strategies should be informed by a detailed understanding of the extent and nature of that harm. Drug...